BR112014027884A2 - combinações farmacêuticas para tratamento de distúrbios metabólicos - Google Patents
combinações farmacêuticas para tratamento de distúrbios metabólicosInfo
- Publication number
- BR112014027884A2 BR112014027884A2 BR112014027884A BR112014027884A BR112014027884A2 BR 112014027884 A2 BR112014027884 A2 BR 112014027884A2 BR 112014027884 A BR112014027884 A BR 112014027884A BR 112014027884 A BR112014027884 A BR 112014027884A BR 112014027884 A2 BR112014027884 A2 BR 112014027884A2
- Authority
- BR
- Brazil
- Prior art keywords
- metabolic disorders
- pharmaceutical combinations
- treatment
- preventing
- diabetes mellitus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
resumo patente de invenção: "combinações farmacêuticas para tratamento de distúrbios metabólicos". a presente invenção refere-se a uma composição farmacêutica que compreende o composto de fórmula (i) ou solvatos, hidratos ou sais farmaceuticamente aceitáveis dos mesmos, em combinação com pelo menos um segundo agente terapêutico 2, que é adequado no tratamento ou prevenção de uma ou mais condições selecionadas dentre diabetes mellitus tipo 1, diabetes mellitus tipo 2, tolerância à glicose prejudicada e hiperglicemia. além disso, a presente invenção refere-se aos métodos para prevenir ou tratar distúrbios metabólicos e condições relacionadas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261644721P | 2012-05-09 | 2012-05-09 | |
US201261645787P | 2012-05-11 | 2012-05-11 | |
PCT/EP2013/059423 WO2013167554A1 (en) | 2012-05-09 | 2013-05-07 | Pharmaceutical combinations for the treatment of metabolic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014027884A2 true BR112014027884A2 (pt) | 2017-06-27 |
Family
ID=48485118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014027884A BR112014027884A2 (pt) | 2012-05-09 | 2013-05-07 | combinações farmacêuticas para tratamento de distúrbios metabólicos |
Country Status (18)
Country | Link |
---|---|
US (3) | US20130303446A1 (pt) |
EP (1) | EP2846797A1 (pt) |
JP (1) | JP2015516404A (pt) |
KR (1) | KR20150014488A (pt) |
CN (1) | CN104427985A (pt) |
AR (1) | AR090999A1 (pt) |
AU (1) | AU2013258109A1 (pt) |
BR (1) | BR112014027884A2 (pt) |
CA (1) | CA2872932A1 (pt) |
CL (1) | CL2014002978A1 (pt) |
EA (1) | EA201401231A1 (pt) |
IL (1) | IL235058A0 (pt) |
IN (1) | IN2014DN08582A (pt) |
MX (1) | MX2014013452A (pt) |
PH (1) | PH12014502448A1 (pt) |
TW (1) | TW201406374A (pt) |
UY (1) | UY34800A (pt) |
WO (1) | WO2013167554A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10383580B2 (en) * | 2012-12-31 | 2019-08-20 | Abbott Diabetes Care Inc. | Analysis of glucose median, variability, and hypoglycemia risk for therapy guidance |
WO2015101916A1 (en) | 2013-12-30 | 2015-07-09 | Mylan Laboratories Ltd. | Process for the preparation of empagliflozin |
PL3207928T3 (pl) * | 2014-10-17 | 2021-08-23 | Hyundai Pharm Co., Ltd. | Preparat złożony, zawierający nową pochodną kwasu 3-(4-(benzyloksy)fenylo)heks-4-ynowego oraz inny składnik czynny, przeznaczony do zapobiegania lub leczenia chorób metabolicznych |
CN109195595A (zh) * | 2016-06-02 | 2019-01-11 | 塞多麦克斯有限公司 | 使用α,α-取代的长链两亲性羧酸盐的糖尿病治疗方案 |
MX2018014743A (es) * | 2016-06-03 | 2019-04-11 | Chemocentryx Inc | Metodo para tratar fibrosis hepatica. |
EP3498279A4 (en) * | 2016-08-12 | 2020-04-29 | Novmetapharma Co., Ltd. | PHARMACEUTICAL COMPOSITION WITH AMODIAQUIN AND ANTIDIABETIC MEDICINAL PRODUCT AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING DIABETES |
NL2019605B1 (en) * | 2017-09-22 | 2019-03-28 | Cfm Pharma Holding B V | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement |
CN110652498B (zh) * | 2019-11-22 | 2022-04-05 | 河南合智医药科技有限公司 | 一种用于治疗2型糖尿病的药物制剂及其制备方法 |
CN112220768A (zh) * | 2020-10-15 | 2021-01-15 | 四川维奥制药有限公司 | 一种米格列醇片剂的制备方法 |
WO2024055932A1 (zh) * | 2022-09-13 | 2024-03-21 | 亚宝药业集团股份有限公司 | 氮杂环化合物、其药物组合物和用于预防和/或治疗疾病的用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2796940B1 (fr) * | 1999-07-26 | 2005-04-08 | Lipha | Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant |
EA011158B1 (ru) | 2004-03-16 | 2009-02-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения |
US7687469B2 (en) | 2004-12-16 | 2010-03-30 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
KR20080102395A (ko) | 2006-02-15 | 2008-11-25 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루코피라노실-치환된 벤조니트릴 유도체, 당해 화합물을 함유하는 약제학적 조성물, 이들의 용도 및 이들의 제조방법 |
JP5384343B2 (ja) | 2006-08-15 | 2014-01-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル−置換シクロプロピルベンゼン誘導体、そのような化合物を含む医薬組成物、sglt阻害剤としてのそれらの使用及びそれらの製造方法 |
EP2079753A1 (en) | 2006-11-06 | 2009-07-22 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
AR078887A1 (es) | 2009-11-06 | 2011-12-07 | Boehringer Ingelheim Int | Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen. |
TWI537258B (zh) * | 2010-11-05 | 2016-06-11 | 百靈佳殷格翰國際股份有限公司 | 六氫茚并吡啶及八氫苯并喹啉之芳基-及雜環芳基羰基衍生物 |
-
2013
- 2013-05-07 CN CN201380023728.XA patent/CN104427985A/zh active Pending
- 2013-05-07 CA CA2872932A patent/CA2872932A1/en not_active Abandoned
- 2013-05-07 BR BR112014027884A patent/BR112014027884A2/pt not_active IP Right Cessation
- 2013-05-07 IN IN8582DEN2014 patent/IN2014DN08582A/en unknown
- 2013-05-07 US US13/888,602 patent/US20130303446A1/en not_active Abandoned
- 2013-05-07 KR KR1020147034475A patent/KR20150014488A/ko not_active Application Discontinuation
- 2013-05-07 WO PCT/EP2013/059423 patent/WO2013167554A1/en active Application Filing
- 2013-05-07 EP EP13724752.4A patent/EP2846797A1/en not_active Withdrawn
- 2013-05-07 MX MX2014013452A patent/MX2014013452A/es unknown
- 2013-05-07 JP JP2015510776A patent/JP2015516404A/ja active Pending
- 2013-05-07 AU AU2013258109A patent/AU2013258109A1/en not_active Abandoned
- 2013-05-07 EA EA201401231A patent/EA201401231A1/ru unknown
- 2013-05-08 TW TW102116415A patent/TW201406374A/zh unknown
- 2013-05-08 AR ARP130101606A patent/AR090999A1/es unknown
- 2013-05-09 UY UY0001034800A patent/UY34800A/es unknown
-
2014
- 2014-09-05 US US14/478,368 patent/US20140378398A1/en not_active Abandoned
- 2014-10-07 IL IL235058A patent/IL235058A0/en unknown
- 2014-11-03 PH PH12014502448A patent/PH12014502448A1/en unknown
- 2014-11-03 CL CL2014002978A patent/CL2014002978A1/es unknown
-
2015
- 2015-11-18 US US14/944,249 patent/US20160067227A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20150014488A (ko) | 2015-02-06 |
PH12014502448A1 (en) | 2015-01-12 |
AR090999A1 (es) | 2014-12-30 |
AU2013258109A1 (en) | 2014-10-30 |
JP2015516404A (ja) | 2015-06-11 |
TW201406374A (zh) | 2014-02-16 |
CL2014002978A1 (es) | 2015-03-13 |
EA201401231A1 (ru) | 2015-08-31 |
CA2872932A1 (en) | 2013-11-14 |
US20130303446A1 (en) | 2013-11-14 |
MX2014013452A (es) | 2014-12-08 |
EP2846797A1 (en) | 2015-03-18 |
US20160067227A1 (en) | 2016-03-10 |
WO2013167554A1 (en) | 2013-11-14 |
CN104427985A (zh) | 2015-03-18 |
US20140378398A1 (en) | 2014-12-25 |
IL235058A0 (en) | 2014-12-31 |
UY34800A (es) | 2013-11-29 |
IN2014DN08582A (pt) | 2015-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014027884A2 (pt) | combinações farmacêuticas para tratamento de distúrbios metabólicos | |
BR112013010021A2 (pt) | combinações farmacêuticas para o tratamento de distúrbios metabólicos. | |
BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
BR112014029868A2 (pt) | compostos, e, composição farmacêutica | |
BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
BRPI0815331B8 (pt) | composição farmacêutica compreendendo um derivado de benzeno glicopiranosil-substituído, bem como seu uso | |
BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
BR112013021236A2 (pt) | composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença | |
BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
BR112015001419A2 (pt) | composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios | |
BR112014004845A2 (pt) | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
BR112015003109A2 (pt) | Composto, composição, uso de um composto, e, métodos para tratar ou prevenir um distúrbio, condição ou doença e para tratar diabetes mellitus tipo 2. | |
BR112015022514A2 (pt) | composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial | |
BR112015012693A2 (pt) | derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
BR112013029269A2 (pt) | "combinação farmacêutica para uso na melhora da tolerância à glicose em pacientes com diabetes tipo 2 e o uso da mesma". | |
BR112015025424A2 (pt) | tratamento de câncer usando terapias de combinação de coenzima q10 | |
BR112016013734A2 (pt) | Composto, composição farmacêutica, kit, e uso de um composto | |
BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
BR112012025592A2 (pt) | moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos | |
BR112014016648A8 (pt) | derivados policíclicos, processo de preparação e uso farmacêutico dos mesmos | |
BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
BR112014025132A2 (pt) | formulações de insulina | |
BR112013029062A2 (pt) | lixisenatida e metformina para o tratamento de diabetes tipo 2 | |
BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |